Understanding how certain genetic elements behave in cancer cells
Characterizing the LINE-1 Retrotransposition-Replication Conflict
This study is looking at how certain genetic elements called LINE-1 can become active in cancer cells and help them grow, especially when there are mutations in genes that usually protect against cancer; by understanding this, the researchers hope to find new ways to treat cancers that have these characteristics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10852869 on NIH RePORTER |
What this research studies
This research investigates the behavior of long interspersed element-1 (LINE-1) sequences in cancer cells, which can become activated and affect cell growth. The researchers aim to understand how mutations in tumor suppressor genes allow cancer cells to thrive despite the presence of LINE-1. They will explore specific DNA repair pathways and replication stress signaling pathways that are essential for these cancer cells. By identifying unique vulnerabilities in LINE-1 positive cells, the research could lead to new therapeutic strategies for treating cancers that exhibit this behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that show activation of LINE-1 sequences, particularly those with mutations in tumor suppressor genes.
Not a fit: Patients whose cancers do not involve LINE-1 activation or those without relevant genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for certain types of cancer by exploiting the vulnerabilities of cancer cells that express LINE-1.
How similar studies have performed: Other research has shown promising results in targeting genetic vulnerabilities in cancer cells, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Burns, Kathleen H — Dana-Farber Cancer Inst
- Study coordinator: Burns, Kathleen H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.